These results from head–neck cancer cells confirm the literature-known pro-tumorigenic effects of HDAC4 and support the hypothesis that class IIa HDACi are beneficial for the treatment of HDAC4 expressing cancers. Here, HDAC4 is linked to head and neck cancer.